CPhI & P-MEC India, organised by Informa Markets, is set to welcome attendees and exhibitors from around the world, both online and in-person, as new CPhI analysis points to sustained pharma growth in India, with an improving outlook for finished dosage, API and biologics. 

The India-specific findings of the CPhI Annual Report survey, conducted among 350 executives, point to a significant jump in the country’s global reputation with India widely perceived to be benefiting from post-pandemic macro-economic and supply chain changes.

With these positive results and growth forecast as the event’s backdrop, the 14th Annual CPhI & P-MEC India will run in a hybrid form, with an online conference and networking from November 15-30 alongside an in-person event in New Delhi on November 24-26.

The online event platform will open more than a week before the start of the in-person event, empowering the industry to maximise the value they get from the in-person CPhI & P-MEC India. This enables companies to identify more partners in advance and pre-qualify their leads. The online platform will also play host to some 30 sessions spanning four tracks – Drug Development and Delivery, API and Next Gen Labs, biosimilars and mAbs and digitization. Running alongside the event is India Pharma week which will host the ‘Women in Pharma’ roundtable as well as the eighth annual India Pharma Awards.

“There is a tremendous need for new manufacturing partners and as shown in the report – Indian manufacturers, in particular, are in high demand. By delivering a hybrid event and offering a platform where international and national buyers and suppliers can profile themselves, we are facilitating a greater opportunity for future partnerships,” commented Silvia Forroova, Brand Director, Informa.